Microflora of the Respiratory Tract in Patients With Cystic Fibrosis and Sensitivity to Antibiotics Based on a 15-Year Follow-Up (2000–2015 Years)

Поликарпова, С. В.; Кондратьева, Е. И.; Shabalova, L.; Пивкина, Н. В.; Жилина, С. В.; Воронкова, А. Ю.; Sherman, V.; Nikonova, V.; Kapranov, N.; Каширская, Н. Ю.; Семыкин, С. Ю.; Амелина, Е. Л.; Красовский, С. А.

doi:10.21518/2079-701x-2016-15-84-89

Cited by 8 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Резистентность (R) установлена к фторхинолонам в 44-51%, к цефалоспоринам Умеренная устойчивость (чувствительность при увеличенной экспозиции антимикробного препарата -I) установлена к полимиксину В -79% (ранее не отмечалась) [8,9], пиперациллин/тазобактаму-75%, к фторхинолонам в 41-48,6% случаев.…”

Section: материал и методыunclassified

“…Цефепим уступал по активности цефтазидиму. Высокая чувствительнось отмечена у препаратов группы фторхинолонов и тобрамицина [9].…”

Section: материал и методыunclassified

“…В 2000-2003 гг. меропенем был активен в отношении 82,5% и 82% плоских и мукоидных штаммов соответственно, в 2012-2015 гг.для 75,8% и 78,9% [9]. В 2018 г. сохранялась высокая чувствительность P. aeruginosa к меропенему -82% штаммов [11].…”

Section: материал и методыunclassified

“…против типичных штаммов P. aeruginosa была 65,1%. [9]. В данном исследовании наибольшей эффективностью обладали также аминогликозиды (71-76%).…”

unclassified

“…Так в 2012-2015 гг. активность цефтазидима была -75,5% и 76,4% против плоских и мукоидных штаммов соответственно, а цефепима -для 59,3% и 58,5% [9]. В 2018 г. к цефтазидиму были чувствительны 85% изолятов P. aeruginosa, к цефепиму -75% выделенных штаммов от детей, больных МВ.…”

unclassified

See 4 more Smart Citations

Characteristics of the frequency and sensitivity to antimicrobial drugs of Staphylococcus aureus and Pseudomonas aeruginosa isolates of the lower respiratory tract of pediatric patients with cystic fibrosis in the Moscow region

Tronza,

Voronkova,

Fatkhullina

et al. 2024

APPS

Self Cite

View full text Add to dashboard Cite

Chronic lung infection is the leading cause of death in patients with cystic fibrosis. The article highlights the data of a microbiological examination of children and adolescents with cystic fibrosis living in the Moscow region and the results of determining the antibiotic susceptibility of the main isolated pathogens. The purpose of the study was to study the spectrum of the microflora of the respiratory tract of children and adolescents with cystic fibrosis with the determination of the antibiotic sensitivity of the isolated strains of S. aureus and P. aeruginosa. Material and methods. A study was made of the discharge of the upper and lower respiratory tract in 127 (66.6%) pediatric patients with cystic fibrosis under the age of 18 years using the bacteriological method of research. Results and discussion. In children and adolescents with cystic fibrosis, S. аureus was isolated from the biological material of the upper and lower respiratory tract in 70.1% of cases, in 46.5% in monoculture and in 24% in association with other microorganisms. P. aeruginosa isolated in 23.6%, in monoculture 8.0%. In most cases, P. aeruginosa was associated with S. аureus. MRSA has been identified in 6.4% of children and adolescents with cystic fibrosis. The studied strains of S. aureus were 33% sensitive to benzylpenicillin, 25% to chloramphenicol and were resistant (75%) to ciprofloxacin. 56% of S. aureus strains remained sensitive to erythromycin. P. aeruginosa strains were resistant to ticarcillin/clavulanate), fluoroquinolones, third-generation cephalosporins, imipenem, and aztreonam. Conclusion. P. aeruginosa retains sensitivity to meropenem and aminoglycosides, and S. aureus to tigecycline, teicoplanin, vancomycin, linezolid, fosfomycin, and fusidic acid. Monitoring the antibiotic susceptibility of microorganisms isolated from patients with cystic fibrosis allows you to optimize the tactics of antimicrobial therapy, taking into account the revision of the criteria of the European Committee for the determination of sensitivity to antimicrobial drugs (EUCAST).

show abstract

Section: материал и методыunclassified

unclassified

See 3 more Smart Citations

Characteristics of the frequency and sensitivity to antimicrobial drugs of Staphylococcus aureus and Pseudomonas aeruginosa isolates of the lower respiratory tract of pediatric patients with cystic fibrosis in the Moscow region

Tronza,

Voronkova,

Fatkhullina

et al. 2024

APPS

Self Cite

View full text Add to dashboard Cite

show abstract

Study of efficacy, safety, and patient satisfaction with inhaled tobramycin (Tobramycin-Gobbi) in children with cystic fibrosis and pseudomonas infection

Kondratyeva

Voronkova

Trishina³

et al. 2021

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Study of efficacy, safety, and patient satisfaction with inhaled tobramycin (Tobramycin-Gobbi) in children with cystic fibrosis and pseudomonas infectionAim of the study was to assess efficacy and safety of Tobramycin-Gobbi in CF, as well as the patients’ satisfaction with the treatment.Methods. 35 children from 6 to 18 years with CF were enrolled in this non-interventional prospective cohort multicenter study. All children had P. aeruginosa in the respiratory tract (newly diagnosed, recurrent, or chronic infection). The children received inhalation treatment with Tobramycin-Gobbi in the following cycles: 28-day treatment/28-day break, for 6 months. The studied parameters included respiratory function, bacterial cultures of the respiratory tract with a bacterial count, growth and body weight, antibiotic therapy for the respiratory episodes. The children and parents filled in a questionnaire “Treatment satisfaction assessment” and assessed their state of health on the visual-analog scale before and after each treatment cycle.Results. P. aeruginosa was eradicated in 17.7% of cases (6 patients, including 2 newly diagnosed, 3 recurrent infections, and 1 chronic infection), reduced bacterial count, decreased number of courses of antibiotic therapy, improvement of FEV1. Adverse reactions were reported by one patient.Conclusion. The efficacy, safety, and tolerability of Tobramicine Gobbi were confirmed in the patients with newly diagnosed, recurrent, and chronic infection caused by P. aeruginosa.

show abstract

Therapy of gram-negative infection in the complex treatment of cystic fibrosis

Voronkova

Zhekaite

Sherman

et al. 2023

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Chronic lung infections are a consequence of the disturbance of mucociliary clearance process in cystic fibrosis. For most patients with cystic fibrosis, chronic lung infection is associated with a poor prognosis. The impact of chronic Pseudomonas aeruginosa infection on progressive deterioration of lung function and nutritional status has been established. Timely and effective antibiotic therapy aimed at eradication or control of gram-negative flora affects the duration and quality of life. The purpose of the study. To investigate the safety and efficacy of inhaled administration of sodium colistimethate (Colimistin®). Methods. The study enrolled 42 patients (27 patients aged 5 to 17 years and 15 patients over 18 years) with an established diagnosis of cystic fibrosis, 38 with monoculture of P. aeruginosa or various associations, 4 with Achromobacter spp. culture. Microbial status, external respiratory function, nutritional status, assessment of well-being, adverse reactions, exacerbations, and use of antibiotic therapy during colimistin inhalations were recorded in all patients at baseline and at 3 months. Results. A significant improvement in nutritional status in terms of weight (p < 0.007) and height (p < 0.001) was shown in the general patient group and the children’s group. In the group of children, there was a significant increase in weight (p < 0.034) and height (p < 0.0001). In the group of patients older than 18 years, there was a significant increase in weight (p < 0.045) and BMI three months after therapy (p < 0.013). There were no significant improvements in FVC and FEV1. The treatment efficacy was shown by the assessment of well-being in the general patient group (p < 0.001) and in the children’s group (p < 0.002). No significant difference was found in the adult patient group (p < 0.067). Two patients dropped out of the study due to ADR at the start of therapy. Conclusion. Sodium colistimethate showed efficacy and safety in bronchopulmonary infections caused by P. aeruginosa in monoculture and in association with Achromobacter spp. and may be recommended for use in children and adults with cystic fibrosis.

show abstract

Microflora of the Respiratory Tract in Patients With Cystic Fibrosis and Sensitivity to Antibiotics Based on a 15-Year Follow-Up (2000–2015 Years)

Cited by 8 publications

References 0 publications

Characteristics of the frequency and sensitivity to antimicrobial drugs of Staphylococcus aureus and Pseudomonas aeruginosa isolates of the lower respiratory tract of pediatric patients with cystic fibrosis in the Moscow region

Characteristics of the frequency and sensitivity to antimicrobial drugs of Staphylococcus aureus and Pseudomonas aeruginosa isolates of the lower respiratory tract of pediatric patients with cystic fibrosis in the Moscow region

Study of efficacy, safety, and patient satisfaction with inhaled tobramycin (Tobramycin-Gobbi) in children with cystic fibrosis and pseudomonas infection

Therapy of gram-negative infection in the complex treatment of cystic fibrosis

Contact Info

Product

Resources

About